載入中
NASDAQHealthcareBiotechnology
最新資料
US$7.25
+US$0.12 · +1.68%
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
前收盤價
US$7.25
+US$0.12 · +1.68%
盤中時間採用ET。市場資料可能有所延遲。
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
日內區間
目前US$7.25
52週區間
目前US$7.25
盤中時間採用ET。市場資料可能有所延遲。
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
日內區間
目前US$7.25
52週區間
目前US$7.25
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.75億 USD | 5525.2萬 USD | 68.2萬 USD | — | — |
| 銷貨成本 | 2259.9萬 USD | 797.3萬 USD | 16.7萬 USD | 62萬 USD | 52.1萬 USD |
| 毛利 | 1.53億 USD | 4727.9萬 USD | 51.5萬 USD | −62萬 USD | −52.1萬 USD |
| 研究與開發 | 3278萬 USD | 3408.2萬 USD | 4989.9萬 USD | 7144.1萬 USD | 7233.8萬 USD |
| 銷售、一般及管理費用 | 2.8億 USD | 2.91億 USD | 1.18億 USD | 1億 USD | 6222.1萬 USD |
| 營業費用 | 3.12億 USD | 3.25億 USD | 1.68億 USD | 1.72億 USD | 1.35億 USD |
| 利息收入 | 704.4萬 USD | 1515.8萬 USD | 787.6萬 USD | 213.2萬 USD | 4.1萬 USD |
| 利息支出 | 6811.5萬 USD | 7200.9萬 USD | 4196.8萬 USD | 2730.5萬 USD | 678.8萬 USD |
| 折舊和攤銷 | 63.3萬 USD | 79.5萬 USD | 57.5萬 USD | 62萬 USD | 52.1萬 USD |
| 營業利益 | −1.6億 USD | −2.77億 USD | −1.67億 USD | −1.72億 USD | −1.35億 USD |
| 淨利 | −2.21億 USD | −3.34億 USD | −2.02億 USD | −1.98億 USD | −1.44億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$17.60
上漲空間 142.76%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1921.34萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM932.17萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF568.32萬0.01%954億 USD0.05%US$235+0.80%
State Street SPDR S&P Pharmaceuticals ETFXPH524.08萬1.14%4.62億 USD0.35%US$64.65+1.60%
iShares Biotechnology ETFIBB281.82萬0.03%108.2億 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO270.51萬0.01%180億 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA217.67萬0.01%218.24億 USD0.03%US$32.79+0.40%
Simplify Propel Opportunities ETFSURI180.72萬2.38%7606.44萬 USD2.82%US$17.06-0.14%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHASimplify Propel Opportunities ETFSURIAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
